1887

Journal of General Virology header logo

Volume 75, Issue 4

Precipitation of the Epstein—Barr virus protein EBNA 2 by an EBNA 3c-specific monoclonal antibody Free

Abstract

Two monoclonal antibodies, E3cD8 and E3cA10, were generated to the EBNA 3 c nuclear protein from the B95.8 isolate of Epstein-Barr virus (EBV). Both antibodies efficiently precipitate EBNA 3c from B95.8- transformed lymphoblastoid cell lines, and E3cA10 also detects EBNA 3c on Western blots. Whereas E3cD8 reacts with all 11 Type-1 isolates of EBV tested, and E3cA10 reacts with 14 of 17 Type-1 isolates, neither antibody detects the EBNA 3 c protein encoded by Type-2 isolates. E3cD8 recognizes a peptide sequence (P/PQAPYQGY) in a repeat region of the B95.8 EBNA 3c coding sequence which is not present in the prototype Type-2 AG876 sequence. The E3cA10 antibody epitope has been mapped to the minimal five amino acid B95.8 peptide, WAPSV, which has an alanine to valine substitution in the AG876 virus isolate. This substitution was also found in three Type-1 EBV isolates that expressed EBNA 3c proteins not detected by E3cA10. In immunoprecipitation studies E3cA10 additionally coprecipitated the EBNA 2 protein from Type-1 isolates of EBV. The possibility of a direct interaction between EBNA 2 and EBNA 3 c was ruled out by the demonstration that the antibody precipitated EBNA 2 from the Raji cell line which carries a virus with a deleted EBNA 3c gene. Since the WAPSV epitope identified in EBNA 3c is not present in EBNA 2, and no EBNA 2 linear peptide reactivity was detected in ELISA, it seems likely that E3cA10 recognizes a conformational epitope on EBNA 2. However, from the present data we cannot exclude the possibility that the antibody reacts with a cellular protein that physically associates with EBNA 2.

  • Received:
  • Accepted:
  • Published Online:
© Society for General Microbiology 1994
Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-75-4-769
1994-04-01
2024-04-23
Loading full text...

Full text loading...

/deliver/fulltext/jgv/75/4/JV0750040769.html?itemId=/content/journal/jgv/10.1099/0022-1317-75-4-769&mimeType=html&fmt=ahah

References

  1. Abbot S. D., Rowe M., Cadwallader K., Ricksten A., Gordon J., Wang F., Rymo L., Rickinson A. B. 1990; Epstein-Barr virus nuclear antigen 2 (EBNA2) induces expression of the virus- coded latent membrane protein (LMP). Journal of Virology 64:2126–2134
     [Google Scholar]
  2. Adldinger H. K., Delius H., Freese U. K., Clarke J., Born-Kamm G. W. 1985; A putative transforming gene of Jijoye virus differs from that of Epstein-Barr virus prototypes. Virology 141:221–234
     [Google Scholar]
  3. Allday M. J., Crawford D. H., Thomas J. A. 1993; Epstein- Barr virus (EBV) nuclear antigen 6 induces expression of the EBV latent membrane protein and an activated phenotype in Raji cells. Journal of General Virology 74:361–369
     [Google Scholar]
  4. Aman P., Rowe M., Kai C., Finke J., Rymo L., Klein E. 1990; Effect of the EBNA-2 gene on the surface antigen phenotype of transfected EBV-negative B-lymphoma lines. International Journal of Cancer 45:77–82
     [Google Scholar]
  5. Baichwal V. R., Sugden B. 1988; Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. Oncogene 2:461–167
     [Google Scholar]
  6. Bodescot M., Chambraud B., Farrell P., Perricaudet M. 1984; Spliced RNA from the IR1-U2 region of Epstein-Barr virus: presence of an open reading frame for a repetitive polypeptide. EMBO Journal 3:1913–1917
     [Google Scholar]
  7. Cohen J. I., Wang F., Mannick J., Kieff E. 1989; Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proceedings of the National Academy of Sciences U.S.A.: 869558–9562
     [Google Scholar]
  8. Dambaugh T., Hennessy K., Chamnankit L., Kieff E. 1984; U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2. Proceedings of the National Academy of Sciences U.S.A.: 817632–7636
     [Google Scholar]
  9. Fåhraeus R., Jansson A., Ricksten A., Sjöblom A., Rymo L. 1990; Epstein-Barr virus-encoded nuclear antigen 2 activates the viral latent membrane protein promoter by modulating the activity of a negative regulatory element. Proceedings of the National Academy of Sciences U.S.A.: 877390–7394
     [Google Scholar]
  10. Grässer F. A., Sauder C., Haiss P., Hille A., Konig S., Gottel S., Kremmer E., Leinenbach H. P., Zeppezauer M., Mueller-Lantzsch N. 1993; Immunological detection of proteins associated with the Epstein-Barr virus nuclear antigen 2A. Virology 195:550–560
     [Google Scholar]
  11. Hammerschmidt W., Sugden B. 1989; Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature; London: 340393–397
     [Google Scholar]
  12. Henderson S., Rowe M., Gregory C., Wang F., Kibff E., Rickinson A. 1991; Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein-1 protects infected B cells from programmed cell death. Cell 65:1107–1115
     [Google Scholar]
  13. Hitt M. M., Allday M. J., Hara T., Karran L., Jones M. D., Busson P., Tursz T., Ernberg I., Griffin B. E. 1989; EBV gene expression in an NPC-related tumour. EMBO Journal 8:2639–2651
     [Google Scholar]
  14. Kieff E., Leibowitz D. 1990; Epstein-Barr virus and its replication. In Virology, 2nd edn.. pp 1889–1920 Fields B. N., Knipe D. M. Edited by New York: Raven Press;
     [Google Scholar]
  15. Mannick J. B., Cohen JI., Birkenbach M., Marchini A., Kieff E. 1991; The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. Journal of Virology 65:6826–6837
     [Google Scholar]
  16. Murray R. J., Kurilla M. G., Griffin H. M., Brooks J. M., Mackett M., Arrand J. R., Rowe M., Burrows S. R., Moss D. J., Kieff E., Rickinson A. B. 1990; Human cytotoxic T cell responses against Epstein-Barr virus nuclear antigens demonstrated using recombinant vaccinia viruses. Proceedings of the National Academy of Sciences U.S.A.: 872906–2910
     [Google Scholar]
  17. Petti L., Sample J., Wang F., Kieff E. 1988; A fifth Epstein-Barr virus nuclear protein (EBNA 3c) is expressed in latently infected growth-transformed lymphocytes. JournalofVirology 62:1330–1338
     [Google Scholar]
  18. Polack A., Delius H., Zimber U., Bornkamm G. W. 1984; Two deletions in the Epstein-Barr virus genome of the Burkitt lymphoma nonproducer line, Raji. Virology 133:146–157
     [Google Scholar]
  19. Pulvertaft R. J. V. 1965; A study of malignant tumours in Nigeria by short-term tissue culture. Journal of Clinical Pathology 18:261–273
     [Google Scholar]
  20. Randahl H., Fåhraeus R., Klein G. 1992; Biochemical characterization of Epstein-Barr virus nuclear antigen 2A and an associated ATPase activity. European Journal of Biochemistry 207:55–59
     [Google Scholar]
  21. Rickinson A. B., Young L. S., Rowe M. 1987; Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. Journal of Virology 61:1310–1317
     [Google Scholar]
  22. Rowe D., Heston L., Metlay J., Miller G. 1985; Identification and expression of a nuclear antigen from the genomic region of the Jijoye strain of Epstein-Barr virus which is missing in its nonimmortalizing deletion mutant P3HR-1. Proceedings of the National Academy of Sciences U.S.A.: 827429–7433
     [Google Scholar]
  23. Rowe M., Evans H. S., Young L. S., Hennessy K., Kieff E., Rickinson A. B. 1987; Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. Journal of General Virology 68:1575–1586
     [Google Scholar]
  24. Rowe M., Young L. S., Cadwallader K., Petti L., Kieff E., Rickinson A. B. 1989; Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins. Journal of Virology 63:1031–1039
     [Google Scholar]
  25. Sample J., Young L., Martin B., Chatman T., Kieff E., Rickinson A., Kieff E. 1990; Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. Journal of Virology 64:4084–4092
     [Google Scholar]
  26. Sung N. S., Kenney S., Gutsch D., Pagano J. S. 1991; EBNA 2 transactivates a lymphoid-specific enhancer in the BamHI c promoter of Epstein-Barr virus. Journal of Virology 65:2164–2169
     [Google Scholar]
  27. Tomkinson B., Robertson E., Kieff E. 1993; Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B- lymphocyte growth transformation. Journal of Virology 67:2014–2025
     [Google Scholar]
  28. Tsang S.-F., Wang F., Izumi K. M., Kieff E. 1991; Delineation of the cis-acting element mediating EBNA-2 transactivation of latent infection membrane protein expression. Journal of Virology 65:6765–6771
     [Google Scholar]
  29. Wang D., Leibowitz D., Kieff E. 1985; An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43:831–840
     [Google Scholar]
  30. Wang D., Leibowitz D., Wang F., Gregory C., Larson R., Springer T., Kieff E. 1988; Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. Journal of Virology 62:4173–4184
     [Google Scholar]
  31. Wang F., Gregory C. D., Rowe M., Rickinson A. B., Wang D., Birkenbach M., Kikutani H., Kishimoto T., Kieff E. 1987; Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proceedings of the National Academy of Sciences U.S.A.: 843452–3456
     [Google Scholar]
  32. Wang F., Gregory C. D., Sample C., Rowe M., Leibowitz D., Murray R., Rickinson A. B., Kieff E. 1990a; Epstein-Barr virus latent membrane protein (LMP-1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA2 and LMP-1 cooperatively induce CD23. Journal of Virology 64:2309–2318
     [Google Scholar]
  33. Wang F., Tsang S.-F., Kurilla M. G., Cohen J. I., Kieff E. 1990b; Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. Journal of Virology 64:3407–3416
     [Google Scholar]
  34. Wang F., Kikutani H., Tsang S.-F., Kishimoto T., Kieff E. 1991; Epstein-Barr virus nuclear protein 2 transactivates a cis- acting CD23 DNA element. Journal of Virology 65:4101–4106
     [Google Scholar]
  35. Woisetschlaegbr M., Jin X. W., Yandava C. N., Furmanski L. A., Strominger J. L., Speck S. H. 1991; Role for the Epstein-Barr virus nuclear antigen 2 in viral promoter switching during the initial stages of infection. Proceedings of the National Academy of Sciences U.S.A.: 883942–3946
     [Google Scholar]
  36. Yates J. L., Warren N., Sugden B. 1984; A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently-infected cells. Proceedings of the National Academy of Sciences U.S.A.: 813806–3810
     [Google Scholar]
  37. Yates J. L., Warren N., Sugden B. 1985; Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature; London: 313812–815
     [Google Scholar]
  38. Young L., Alfieri C., Hennessey K., Evans H., O’Hara C., Anderson K.C.RITZ, Shapiro R. S., Rickinson A., Kieff E., Cohen JI. 1989; Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lympho- proliferative disease. New England Journal of Medicine 321:1080–1085
     [Google Scholar]
  39. Zimber-Strobl U., Kremmer E., Grässer F., Marschall G., Laux G., Bornkamm G. W. 1993; The Epstein-Barr virus nuclear antigen 2 interacts with the EBNA-2-responsive cis-element in the terminal protein 1 gene promoter. EMBO Journal 12:167–175
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-75-4-769
Loading
Precipitation of the Epstein—Barr virus protein EBNA 2 by an EBNA 3c-specific monoclonal antibody
J. Gen. Virol. 75, 769 (1994); https://doi.org/10.1099/0022-1317-75-4-769
/content/journal/jgv/10.1099/0022-1317-75-4-769
/content/journal/jgv/10.1099/0022-1317-75-4-769
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error